Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis

The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart (R) electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) beta-1 alpha (Rebif (R)). The aim of the study was to...

Descripción completa

Detalles Bibliográficos
Autores: Fernández, O., Arroyo, R., Martínez Yélamos, Sergio, Marco, M., García Merino, Juan Antonio, Muñoz, D., Merino Cabrera, Esperanza, Roque, A.
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:2445/126822
Acceso en línea:https://hdl.handle.net/2445/126822
Access Level:acceso abierto
Palabra clave:Esclerosi múltiple
Interferó
Multiple sclerosis
Interferon
id ES_dcee4b2a665620d334dcb435f0daf20e
oai_identifier_str oai:recercat.cat:2445/126822
network_acronym_str ES
network_name_str España
repository_id_str
spelling Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple SclerosisFernández, O.Arroyo, R.Martínez Yélamos, SergioMarco, M.García Merino, Juan AntonioMuñoz, D.Merino Cabrera, EsperanzaRoque, A.Esclerosi múltipleInterferóMultiple sclerosisInterferonThe effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart (R) electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) beta-1 alpha (Rebif (R)). The aim of the study was to determine long-term adherence to this treatment in patients with relapsing-remitting multiple sclerosis (RRMS). This retrospective multicentre observational study analysed 258 patients with RRMS who were receiving sc IFN beta-1 alpha (Rebif (R)) treatment by using RebiSmart (R) until replacement (36 months maximum lifetime) or treatment discontinuation. Adherence was calculated with data (injection dosage, time, and date) automatically recorded by RebiSmart (R). Patients in the study had a mean age of 41 years with a female proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6-1.9). Overall adherence was 92.6%(95% CI, 90.6-94.5%). A total of 30.2% of patients achieved an adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a suboptimal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initiation. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning of the treatment was the only variable significantly related to achieving an adherence of at least 80% (OR = 3.06, 1.28-7.31). Results of this study indicate that sc IFN beta-1 alpha administration facilitated by RebiSmart (R) could lead to high rates of adherence to a prescribed dose regimen over 36 months.Public Library of Science (PLoS)2018201820162018info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion12 p.application/pdfhttps://hdl.handle.net/2445/126822Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))reponame:Recercat. Dipósit de la Recerca de Catalunyainstname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)InglésReproducció del document publicat a: https://doi.org/10.1371/journal.pone.0160313PLoS One, 2016, vol. 11, num. 8, p. e0160313https://doi.org/10.1371/journal.pone.0160313cc by (c) Fernández et al., 2016http://creativecommons.org/licenses/by/3.0/es/info:eu-repo/semantics/openAccessoai:recercat.cat:2445/1268222026-05-29T05:05:01Z
dc.title.none.fl_str_mv Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
title Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
spellingShingle Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
Fernández, O.
Esclerosi múltiple
Interferó
Multiple sclerosis
Interferon
title_short Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
title_full Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
title_fullStr Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
title_full_unstemmed Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
title_sort Long-Term Adherence to IFN Beta-1a Treatment when Using RebiSmart® Device in Patients with Relapsing-Remitting Multiple Sclerosis
dc.creator.none.fl_str_mv Fernández, O.
Arroyo, R.
Martínez Yélamos, Sergio
Marco, M.
García Merino, Juan Antonio
Muñoz, D.
Merino Cabrera, Esperanza
Roque, A.
author Fernández, O.
author_facet Fernández, O.
Arroyo, R.
Martínez Yélamos, Sergio
Marco, M.
García Merino, Juan Antonio
Muñoz, D.
Merino Cabrera, Esperanza
Roque, A.
author_role author
author2 Arroyo, R.
Martínez Yélamos, Sergio
Marco, M.
García Merino, Juan Antonio
Muñoz, D.
Merino Cabrera, Esperanza
Roque, A.
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Esclerosi múltiple
Interferó
Multiple sclerosis
Interferon
topic Esclerosi múltiple
Interferó
Multiple sclerosis
Interferon
description The effectiveness of disease-modifying drugs in the treatment of multiple sclerosis is associated with adherence. RebiSmart (R) electronic device provides useful information about adherence to the treatment with subcutaneous (sc) interferon (IFN) beta-1 alpha (Rebif (R)). The aim of the study was to determine long-term adherence to this treatment in patients with relapsing-remitting multiple sclerosis (RRMS). This retrospective multicentre observational study analysed 258 patients with RRMS who were receiving sc IFN beta-1 alpha (Rebif (R)) treatment by using RebiSmart (R) until replacement (36 months maximum lifetime) or treatment discontinuation. Adherence was calculated with data (injection dosage, time, and date) automatically recorded by RebiSmart (R). Patients in the study had a mean age of 41 years with a female proportion of 68%. Mean EDSS score at start of treatment was 1.8 (95% CI, 1.6-1.9). Overall adherence was 92.6%(95% CI, 90.6-94.5%). A total of 30.2% of patients achieved an adherence rate of 100%, 80.6% at least 90%, and only 13.2% of patients showed a suboptimal adherence (<80%). A total of 59.9% of subjects were relapse-free after treatment initiation. Among 106 subjects (41.1%) who experienced, on average, 1.4 relapses, the majority were mild (40.6%) or moderate (47.2%). Having experienced relapses from the beginning of the treatment was the only variable significantly related to achieving an adherence of at least 80% (OR = 3.06, 1.28-7.31). Results of this study indicate that sc IFN beta-1 alpha administration facilitated by RebiSmart (R) could lead to high rates of adherence to a prescribed dose regimen over 36 months.
publishDate 2016
dc.date.none.fl_str_mv 2016
2018
2018
2018
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://hdl.handle.net/2445/126822
url https://hdl.handle.net/2445/126822
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Reproducció del document publicat a: https://doi.org/10.1371/journal.pone.0160313
PLoS One, 2016, vol. 11, num. 8, p. e0160313
https://doi.org/10.1371/journal.pone.0160313
dc.rights.none.fl_str_mv cc by (c) Fernández et al., 2016
http://creativecommons.org/licenses/by/3.0/es/
info:eu-repo/semantics/openAccess
rights_invalid_str_mv cc by (c) Fernández et al., 2016
http://creativecommons.org/licenses/by/3.0/es/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 12 p.
application/pdf
dc.publisher.none.fl_str_mv Public Library of Science (PLoS)
publisher.none.fl_str_mv Public Library of Science (PLoS)
dc.source.none.fl_str_mv Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
reponame:Recercat. Dipósit de la Recerca de Catalunya
instname:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
instname_str Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
reponame_str Recercat. Dipósit de la Recerca de Catalunya
collection Recercat. Dipósit de la Recerca de Catalunya
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869421814239723520
score 15,811543

Similares en LA Referencia